NWPF

News ArchivesRead News

Scientists image brain structures that deteriorate in Parkinson's

Tuesday November 27, 2012

A new imaging technique developed at MIT offers the first glimpse of the degeneration of two brain structures affected by Parkinson's disease.
Anne Trafton

Medicalxpress.com - The technique, which combines several types of magnetic resonance imaging (MRI), could allow doctors to better monitor patients' progression and track the effectiveness of potential new treatments, says Suzanne Corkin, MIT professor emerita of neuroscience and leader of the research team. The first author of the paper is David Ziegler, who received his PhD in brain and cognitive sciences from MIT in 2011.

The study, appearing in the Nov. 26 online edition of the Archives of Neurology, is also the first to provide clinical evidence for the theory that Parkinson's neurodegeneration begins deep in the brain and advances upward.

"This progression has never been shown in living people, and that's what was special about this study. With our new imaging methods, we can see these structures more clearly than anyone had seen them before," Corkin says.

Parkinson's disease currently affects 1 to 2 percent of people over 65, totaling five million people worldwide. The disease gradually destroys the brain cells that control movement, leaving most patients wheelchair-bound and completely dependent on caregivers. "A major obstacle to research on the causes and progression of this disease has been a lack of effective brain imaging methods for the areas affected by the disease," Ziegler says.

In 2004, Heiko Braak, an anatomist at Johann Wolfgang Goethe University in Frankfurt, Germany, classified Parkinson's disease into six stages, based on the appearances of the affected brain structures. He proposed that during the earliest stages, a structure deep inside the brain, known as the substantia nigra, begins to degenerate. This structure is critical for movement and also plays important roles in reward and addiction.

Later, Braak proposed, degeneration spreads outward to a brain region known as the basal forebrain. This area, located behind the eyes, includes several structures that produce acetylcholine, a neurotransmitter important for learning and memory.

Neuropathologists (scientists who study the brains of deceased patients) had found evidence for this sequence of events, but it had never been observed in living patients because the substantia nigra, deep within the brain, is so difficult to image with conventional MRI.

To overcome that, the MIT team used four types of MRI scans, each of which uses slightly different magnetic fields, generating different images. By combining these scans, the researchers created composite images of each patient's brain that clearly show the substantia nigra and basal forebrain. "Our new MRI methods provide an unparalleled view of these two structures, allowing us to calculate the precise volumes of each structure," Ziegler says.

After scanning normal brains, the researchers studied 29 early-stage Parkinson's patients. They found significant loss of volume in the substantia nigra early on, followed by loss of basal forebrain volume later in the disease, as predicted by Braak.

In future studies, this MRI technique could be used to follow patients over time and measure whether degeneration of the two areas is correlated or if they deteriorate independently of one another, Corkin says.

This approach could also give doctors a new way to monitor how their patients are responding to treatment, she says. (Most patients are treated with dopamine, which helps to overcome the loss of dopamine-producing neurons in the substantia nigra.) Researchers could also use the new imaging tools to determine the effects of potential new treatments.

Recent News

Aug 24 - Study Details Process Involved in Parkinson’s Disease
Aug 20 - Two proteins work together to help cells eliminate trash; Parkinson's may result
Aug 17 - Scientists visualize critical part of basal ganglia pathways
Aug 17 - VA benefits office seeks all vets exposed to Agent Orange
Aug 12 - New, rapid dementia screening tool rivals 'gold standard' clinical evaluations
Aug 11 - Strolling in Seaside, fighting Parkinson's
Aug 11 - Scientists probing molecular origins of Parkinson's disease highlight two proteins
Aug 11 - Could Chocolate Help To Ease Parkinson’s Disease?
Aug 10 - Take 2: Why Seattle should try to replicate Spokane’s 3-on-3 Hoopfest success
Aug 10 - Book Review: A voyage into Parkinson’s disease, led by patient and journalist
Aug 10 - Parkinson's could be slowed with existing drug
Aug 7 - Opinion: Why modern life is making dementia in your 40s more likely
Aug 3 - Software Turns Smartphones into Tools for Medical Research
Jul 31 - Innovative Technology Using Dragonflies Might Offer Insights Into Human Brain Function
Jul 27 - Low-dose lithium reduces side effects from most common treatment for Parkinson's disease
Jul 27 - Opinion: Parkinson's disease creating class of workers who fear for their jobs: PennLive letters
Jul 22 - Parkinson's: Diabetes drug may offer clue to treatment
Jul 19 - Alzheimer's Drugs in the Works Might Treat Other Diseases, Too
Jul 17 - Parkinson's disease may be treatable with antimalaria drugs
Jul 16 - Virtual research studies feasible